Piroxicam nanoparticles for ocular delivery: Physicochemical characterization and implementation in endotoxin-induced uveitis

被引:108
作者
Adibkia, Khosro
Shadbad, Mohammad Reza Siahi
Nokhodchi, Ali
Javadzedeh, Alireza
Barzegar-Jalali, Mohammad
Barar, Jaleh
Mohammadi, Ghobad
Omidi, Yadollah [1 ]
机构
[1] Tabriz Univ Med Sci, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran
[2] Tabriz Univ Med Sci, Fac Pharm, Tabriz, Iran
[3] Univ Greenwich, Medway Sch Pharm, Chatham ME4 4TB, Kent, England
关键词
endotoxin-induced uveitis; Eudragit (R) RS100; nanomedicines; nanotechnology; piroxicam; ocular delivery systems; DRUG-DELIVERY; IN-VITRO; EUDRAGIT RS100(R); TNF-ALPHA; NANOSUSPENSIONS; MICROSPHERES; INFLAMMATION; IBUPROFEN; RELEASE; VIVO;
D O I
10.1080/10611860701453125
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
To investigate the anti-inflammatory impacts of piroxicam nanosuspension, in the current investigation, piroxicam:Eudragit((R)) RS100 nanoformulations were used to control inflammatory symptoms in the rabbits with endotoxin-induced uveitis (EIU). The nanoparticles of piroxicam:Eudragit((R))RS100 was formulated using the solvent evaporation/extraction technique. The morphological and physicochemical characteristics of nanoparticles were studied using particle size analysis, X-ray crystallography, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy (SEM). Drug release profiles were examined by fitting the data to the most common kinetic models. Selected nanosuspensions were used to assess the anti-inflammatory impacts of piroxicam nanoparticles in the rabbits with EIU. The major symptoms of EIU (i.e. inflammation and leukocytes numbers in the aqueous humor) were examined. All the prepared piroxicam formulations using Eudragit((R))RS100 resulted in a nano-range size particles and displayed spherical smooth morphology with positively charged surface, however, the formulated particles of drug alone using same methodology failed to manifest such characteristics. The Eudragite((R))RS100 containing nanoparticles displayed lower crystallinity than piroxicam with no chemical interactions between the drug and polymer molecules. Kinetically, the release profiles of piroxicam from nanoparticles appeared to fit best with the Weibull model and diffusion was the superior phenomenon. The in vivo examinations revealed that the inflammation can be inhibited by the drug:polymer nanosuspension more significantly than the microsuspension of drug alone in the rabbits with EIU. Upon these findings, we propose that the piroxicam:Eudragit((R))RS100 nanosuspensions may be considered as an improved ocular delivery system for locally inhibition of inflammation.
引用
收藏
页码:407 / 416
页数:10
相关论文
共 44 条
[21]   THERMOANALYTICAL AND IR-SPECTROSCOPICAL INVESTIGATIONS ON POLYMORPHIC DRUGS - ACEMETACINE, PIROXICAM, PROPRANOLOL HYDROCHLORIDE AND URAPIDIL [J].
KUHNERTBRANDSTATTER, M ;
VOLLENKLEE, R .
FRESENIUS ZEITSCHRIFT FUR ANALYTISCHE CHEMIE, 1985, 322 (02) :164-169
[22]   STEROIDAL AND NONSTEROIDAL DRUGS IN ENDOTOXIN-INDUCED UVEITIS [J].
KULKARNI, PS .
JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (01) :329-334
[23]   OCULAR DRUG-DELIVERY CONVENTIONAL OCULAR FORMULATIONS [J].
LANG, JC .
ADVANCED DRUG DELIVERY REVIEWS, 1995, 16 (01) :39-43
[24]   ENDOTOXIN-INDUCED UVEITIS IN THE MOUSE - SUSCEPTIBILITY AND GENETIC-CONTROL [J].
LI, Q ;
PENG, B ;
WHITCUP, SM ;
JANG, SU ;
CHAN, CC .
EXPERIMENTAL EYE RESEARCH, 1995, 61 (05) :629-632
[25]  
Marie O, 1999, INVEST OPHTH VIS SCI, V40, P2275
[26]  
MAUDGAL PC, 1989, GRAEFES ARCH OPHTHAL, V216, P191
[27]  
MICHELLE L, 2005, J AM OPTOM ASSOC, V76, P450
[28]   EFFECTS OF STEROIDS AND IMMUNOSUPPRESSIVE DRUGS ON ENDOTOXIN-UVEITIS IN RABBITS [J].
OHIA, EO ;
MANCINO, M ;
KULKARNI, PS .
JOURNAL OF OCULAR PHARMACOLOGY, 1992, 8 (04) :295-307
[29]   On the use of the Weibull function for the discernment of drug release mechanisms [J].
Papadopoulou, V ;
Kosmidis, K ;
Vlachou, M ;
Macheras, P .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 309 (1-2) :44-50
[30]   Nanosuspensions: a promising drug delivery strategy [J].
Patravale, VB ;
Date, AA ;
Kulkarni, RM .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2004, 56 (07) :827-840